1. Home
  2. GEVO vs PRTA Comparison

GEVO vs PRTA Comparison

Compare GEVO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gevo Inc.

GEVO

Gevo Inc.

HOLD

Current Price

$1.98

Market Cap

468.8M

Sector

Industrials

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.61

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEVO
PRTA
Founded
2005
2012
Country
United States
Ireland
Employees
151
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
468.8M
539.9M
IPO Year
2010
2013

Fundamental Metrics

Financial Performance
Metric
GEVO
PRTA
Price
$1.98
$10.61
Analyst Decision
Buy
Buy
Analyst Count
3
9
Target Price
$6.42
$19.00
AVG Volume (30 Days)
4.4M
462.3K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
58.82
N/A
EPS
N/A
N/A
Revenue
$711,000.00
$814,000.00
Revenue This Year
$19.44
$1,111.38
Revenue Next Year
$5.59
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$4.32
52 Week High
$2.97
$11.69

Technical Indicators

Market Signals
Indicator
GEVO
PRTA
Relative Strength Index (RSI) 41.32 64.85
Support Level $1.94 $9.69
Resistance Level $2.19 $10.90
Average True Range (ATR) 0.20 0.41
MACD -0.07 0.11
Stochastic Oscillator 10.36 95.21

Price Performance

Historical Comparison
GEVO
PRTA

About GEVO Gevo Inc.

Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: